Section Arrow
APGE.NASDAQ
- Apogee Therapeutics
Quotes are at least 15-min delayed:2025/07/20 13:10 EDT
Regular Hours
Last
 39.31
+0.31 (+0.79%)
Day High 
40.4 
Prev. Close
39 
1-M High
47.71 
Volume 
824.77K 
Bid
37.82
Ask
39.47
Day Low
38.58 
Open
39.42 
1-M Low
35.71 
Market Cap 
2.27B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 39.02 
20-SMA 41.02 
50-SMA 39.97 
52-W High 63.5 
52-W Low 26.2 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.61/-4.53
Enterprise Value
2.28B
Balance Sheet
Book Value Per Share
11.55
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
NCNANuCana plc0.0477+0.0009+1.92%-- 
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Quotes are at least 15-min delayed:2025/07/20 13:10 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.